Smith CA - Search Results

1

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Rooney CM, et al. Among authors: smith ca. Blood. 1998 Sep 1;92(5):1549-55. Blood. 1998. PMID: 9716582 Free article.

2

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Smith CA, et al. J Hematother. 1995 Apr;4(2):73-9. doi: 10.1089/scd.1.1995.4.73. J Hematother. 1995. PMID: 7633844

3

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Rooney CM, et al. Among authors: smith ca. Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2. Lancet. 1995. PMID: 7799740

4

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Heslop HE, et al. Among authors: smith ca. Nat Med. 1996 May;2(5):551-5. doi: 10.1038/nm0596-551. Nat Med. 1996. PMID: 8616714

5

Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.

Rooney CM, Smith CA, Heslop HE. Rooney CM, et al. Among authors: smith ca. Mol Med Today. 1997 Jan;3(1):24-30. doi: 10.1016/S1357-4310(96)10054-X. Mol Med Today. 1997. PMID: 9021739 Review.

6

Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.

Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. Smith CA, et al. Leuk Lymphoma. 1996 Oct;23(3-4):213-20. doi: 10.3109/10428199609054823. Leuk Lymphoma. 1996. PMID: 9031101 Review.

7

Immunotherapy for Epstein-Barr virus-associated cancers.

Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Rooney CM, et al. Among authors: smith ca. J Natl Cancer Inst Monogr. 1998;(23):89-93. doi: 10.1093/oxfordjournals.jncimonographs.a024180. J Natl Cancer Inst Monogr. 1998. PMID: 9709309

8

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. Gottschalk S, et al. Among authors: smith ca. Blood. 2001 Feb 15;97(4):835-43. doi: 10.1182/blood.v97.4.835. Blood. 2001. PMID: 11159505 Free article.

9

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Heslop HE, et al. Among authors: smith ca. Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30. Blood. 2010. PMID: 19880495 Free PMC article. Clinical Trial.

10

Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro.

Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Smith CA, et al. J Virol. 1996 Oct;70(10):6733-40. doi: 10.1128/JVI.70.10.6733-6740.1996. J Virol. 1996. PMID: 8794310 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,998 results

Search Page

Filters